Advances in Therapy

, Volume 24, Issue 1, pp 123–134 | Cite as

Appropriate intervention strategies for weight gain induced by olanzapine: A randomized controlled study

  • W. Milano
  • F. Grillo
  • A. Del Mastro
  • M. De Rosa
  • B. Sanseverino
  • C. Petrella
  • A. Capasso


Weight gain induced by antipsychotics is the second most frequently given reason for noncompliance with pharmacologic therapy; excessive sedative effects rank first, with extrapyramidal side effects ranking third. Frequently, weight gain leads to inconsistent pharmacologic treatment; this exposes patients to the risk of recurrent symptoms. In fact, one of the key contributors to good clinical outcomes in schizophrenic patients is compliance with pharmacologic treatment. The goals of this study were to evaluate weight gain in a group of patients treated with olanzapine, diet modifications, and moderate physical activity and to compare the findings with those from a second group of patients who were given only olanzapine treatment. For 8 wk, investigators followed 2 groups of patients suffering from schizophrenia and hypomania in bipolar disorder, according to the nosographic criteria ofThe Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The first group (A) of 18 patients (9 female, 9 male) affected by manic episodes in bipolar disorder received olanzapine (10–20 mg/d), jogged lightly for 30 min 3 times a week, and complied with a diet that consisted of 500 kcal/d less than usual. The second group (B) of 10 patients (4 female, 6 male) with schizophrenia received only olanzapine (10–20 mg/d). All patients from both groups were weighed at the beginning of the observation period and weekly thereafter for 2 mo. After 2 mo of observation, group A showed a mean weight gain of 1.47 kg, whereas group B exhibited a mean weight gain of 3.5 kg; the difference between the 2 groups was almost 2 kg (P<.005). Group A showed a statistically significant reduction in weight gain compared with group B, clearly demonstrating the effectiveness of moderate physical activity and diet therapy in reducing weight gain in atypical antipsychotic treatment. Therefore, patient weight and body mass index must be monitored during the first weeks of antipsychotic treatment, with the goals of avoiding significant weight gain and treatment interruption.


obesity antipsychotics olanzapine schizophrenia weight gain 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hardman JG, Limbird LE, Goodman Gilman A (eds.)Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. New York, NY: McGraw-Hill; 2001.Google Scholar
  2. 2.
    Pijl H, Meinders E. Bodyweight change as an adverse effect of drug treatment.Drug Safety. 1996; 4:329–342.CrossRefGoogle Scholar
  3. 3.
    Sussman N, Ginsberg D. Effects of psychotropic drugs on weight.Psychiatr Ann. 1999;29:580–594.Google Scholar
  4. 4.
    Zinnerman U, Kraus T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.J Psychiatry Res. 2003;37:193–220.CrossRefGoogle Scholar
  5. 5.
    Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology.Psychiatr Serv. 2002;53:842–847.PubMedCrossRefGoogle Scholar
  6. 6.
    Aquila R, Emanuel M. Interventions for weight gain in adults treated with novel antipsychotics: primary care companion.J Clin Psychiatry. 2000;2:20–23.Google Scholar
  7. 7.
    Birt J. Management of weight gain associated with antipsychotics.Ann Clin Psychiatry. 2003; 15:49–58.PubMedCrossRefGoogle Scholar
  8. 8.
    Pancheri P. Farmacoterapia psichiatrica. Masson, ed; 2003.Google Scholar
  9. 9.
    Allison BD, Casey D. Antipsychotic-induced weight gain: a review of the literature.J Clin Psychiatry. 2001;62(suppl 7):22–31.PubMedGoogle Scholar
  10. 10.
    Marder SR, Essock SM. Physical health monitoring of patients with schizophrenia.Am J Psychiatry. 2004;161:1334–1349.PubMedCrossRefGoogle Scholar
  11. 11.
    Melkerson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics.Drugs. 2004;64:701–723.CrossRefGoogle Scholar
  12. 12.
    Kurzthaler I, Fleischacker W. The clinical implications of weight gain in schizophrenia.J Clin Psychiatry. 2001;62(suppl 7):32–37.PubMedGoogle Scholar
  13. 13.
    LIGIO 1999 Linee Guida Italiane Obesità. Pendragon Edizioni Bologna.Google Scholar
  14. 14.
    Blin O, Micallef J. Antipsychotic associated weight gain and clinical outcome parameters.J Clin Psychiatry. 2001;62(suppl 7):11–21.PubMedGoogle Scholar
  15. 15.
    Taylor DM, McAskill R. Atypical antipsychotic and weight gain: a systematic review.Acta Psychiatr Scand. 2000;101:416–432.PubMedCrossRefGoogle Scholar
  16. 16.
    Sussman N. Review of atypical antipsychotic and weight gain.J Clin Psychiatry. 2001;(suppl 23): 292–293.Google Scholar
  17. 17.
    Malhotra S, McElroy S. Medical management of obesity associated with mental disorders.J Clin Psychiatry. 2002;63(suppl 4):32.Google Scholar
  18. 18.
    Milano W. Dismetabolismi in corso di trattamento con antipsicotici: obesità e sindrome metabolica. Masson, ed; 2005.Google Scholar
  19. 19.
    Baptista T, Kin N, Beaulieu S. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.Pharmacopsychiatry. 2002;35:205–219.PubMedCrossRefGoogle Scholar
  20. 20.
    Wirshing D. Adverse effects of atypical antipsychotics.J Clin Psychiatry. 2001;62(suppl 21):7.PubMedGoogle Scholar
  21. 21.
    Kahn BB, Lier JS. Obesity and insulin resistance.J Clin Invest. 2000;106:473–481.PubMedCrossRefGoogle Scholar
  22. 22.
    Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis and type 2 diabetes mellitus in patients treated with atypical antipsychotics.J Clin Psychiatry. 2001; (suppl 27):10-14.Google Scholar
  23. 23.
    Bluher S, Mantzoros CS. The role of leptin in regulating neuroendocrine function in humans.J Nutr. 2004;134:2469S-2474S.PubMedGoogle Scholar
  24. 24.
    Monteleone P, Fabrazzo M, Tortorella A, May M. Pronounced, early increase in circulating leptin predicts lower weight gain during clozapine treatment.J Clin Psychopharmacol. 2002;22:424–426.PubMedCrossRefGoogle Scholar
  25. 25.
    Monteleone P, Di Lieto A, Tortorella A, Maj M. Circulating leptin in patients with anorexia nervosa, bulimia nervosa or binge eating disorder: relationship to body weight, eating patterns, psychopathology and endocrine changes.Psychiatr Res. 2000;94:121–129.CrossRefGoogle Scholar
  26. 26.
    Kraus T, Haack M, Schuld A, Kuhn M, Uhr M, Pollmacher T. Body weight and leptin levels during treatment with antipsychotic drugs.Am J Psychiatry. 1999;156:312–314.PubMedGoogle Scholar
  27. 27.
    Bromel T, Blum WF, Ziegler A, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy.Mol Psychiatry. 1998;3:76–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Hagg S, Soderberg S, Olsson T, Mjorndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics.J Clin Psychiatry. 2001;62:843–848.PubMedCrossRefGoogle Scholar
  29. 29.
    Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.J Clin Psychiatry. 2003;64:598–604.PubMedCrossRefGoogle Scholar
  30. 30.
    Baptista T, Lacruz A, Silvera R, Mendoza S, Hernandez L. Endocrine and metabolic profile in the obesity associated with typical antipsychotic drug administration.Pharmacopsychiatry. 2001;34:223–231.PubMedGoogle Scholar
  31. 31.
    Baptista T, Lacruz A. Endocrine and metabolic profile in obesity associated with typical antipsychotic drug-administration.Pharmacopsychiatry. 2001;34:223–231.PubMedGoogle Scholar
  32. 32.
    Bjorntorp P. Regional obesity. In: Bjorntrop P, Brodoff BN (eds.)Obesity. Philadelphia, Pa: JB Lippincott; 1992:579–586.Google Scholar
  33. 33.
    Baptista T, Reyes D. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation.Pharmacol Biochem Behav. 1999;62:409–417.PubMedCrossRefGoogle Scholar
  34. 34.
    Baptista T, Alastre T, Contreras Q. Effects of the antipsychotic drugs sulpiride on reproductive hormones in healthy men: relationship with body weight regulation.Pharmacopsychiatry. 1997; 30:250–255.PubMedCrossRefGoogle Scholar
  35. 35.
    Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.Drugs. 2004;64:2291–2314.PubMedCrossRefGoogle Scholar
  36. 36.
    Hester EK, Thrower MR. Current options in the management of olanzapine-associated weight gain.Ann Pharmacother. 2005;39:302–310.PubMedCrossRefGoogle Scholar
  37. 37.
    Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management.Acta Psychiatr Scand. 1999;100:3–16.PubMedCrossRefGoogle Scholar
  38. 38.
    Baptista T, Lacruz A, Meza T, Herandez L. Antipsychotic drugs and obesity: is prolactin involved?Can J Psychiatry. 2001;46:829–834.PubMedGoogle Scholar
  39. 39.
    Mihara K, Kondo T, Suzuki A. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene.Psychopharmacology. 2000;149:246–250.PubMedCrossRefGoogle Scholar
  40. 40.
    Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity.Lancet. 2001;357:354–357.PubMedCrossRefGoogle Scholar
  41. 41.
    National Institutes of Health, National Heart, Lung and Blood Institute.The Clinical Guidelines on Identification, Evaluation and Treatment of Overweight and Obesity in the Adult: The Evidence Report. Bethesda, Md: NHLBI; 1998. NIH Publication No. 98-4083.Google Scholar
  42. 42.
    Aquila R. Management of weight gain in patients with schizophrenia.J Clin Psychiatry. 2002; 63(suppl 4):33–36.PubMedGoogle Scholar
  43. 43.
    Kurzthaler I, Flischacker W. The clinical implications of weight gain in schizophrenia. JClin Psychiatry. 2001;62(suppl 7):32–37.PubMedGoogle Scholar

Copyright information

© Health Communications Inc 2007

Authors and Affiliations

  • W. Milano
    • 1
  • F. Grillo
    • 1
  • A. Del Mastro
    • 1
  • M. De Rosa
    • 1
  • B. Sanseverino
    • 1
  • C. Petrella
    • 1
  • A. Capasso
    • 2
  1. 1.Mental Health UnitNaplesItaly
  2. 2.Department of Pharmaceutical SciencesUniversity of SalernoFisciano (Salerno)Italy

Personalised recommendations